Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.53) per share for the quarter.
Enliven Therapeutics Trading Down 2.1 %
Shares of ELVN traded down $0.46 during midday trading on Friday, reaching $21.00. The stock had a trading volume of 347,272 shares, compared to its average volume of 237,554. The firm has a 50 day simple moving average of $21.84 and a 200-day simple moving average of $23.90. Enliven Therapeutics has a one year low of $10.90 and a one year high of $30.03. The firm has a market cap of $1.03 billion, a PE ratio of -11.05 and a beta of 1.04.
Insider Transactions at Enliven Therapeutics
In other news, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $265,330. This trade represents a 20.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the sale, the chief operating officer now owns 329,977 shares of the company's stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,117 shares of company stock worth $949,435. 29.20% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ELVN. BTIG Research began coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective for the company. Robert W. Baird raised their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of "Buy" and an average price target of $38.25.
Read Our Latest Stock Analysis on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
